Learn more about:
Lasting reductions in exacerbations for up to 4.8 years 1
Reduction beyond benralizumab (indirect treatment comparison) 7
See also:
See also:
Nucala is the only anti-IL-5 to demonstrate sustained reduction in blood eosinophils for up to 4.8 years 1
See also:
Nucala is the only anti-IL-5 with up to 4.8 years of clinical trial safety data 1
In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within the first 3 injections. 6
Most common AEs and SAEs in adults
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 6
See also:
Indication:
Severe Eosinophilic Asthma
NUCALA is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 6 years and older
Dosage:
Adults and Adolescents (12 years and older)
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children aged 6 to 11 years old:
Children weighing ≥ 40 kg
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children weighing < 40 kg
The recommended dose is 40 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks
Data available in the paediatric patient population 16
Limited data were collected in patients under 18 years of age in the Nucala development programme. A small PK/PD study in children 6-11 years was conducted (Study 200363, n=36). To confirm the value of Nucala in the paediatric population, a 5-step extrapolation approach was taken.
Study |
Paediatric subjects |
Total subjects |
Dose† |
---|---|---|---|
DREAM |
1 (12 – 17 years) |
616 |
75, 250, 750 mg IV |
MENSA |
25 (12 – 17 years) |
576 |
75 mg IV 100 mg SC |
SIRIUS |
2 (12 – 17 years) |
135 |
100 mg SC |
MUSCA |
9 (12 – 17 years) |
551 |
100 mg SC |
Study 200363 |
36 (6-11 years) |
36 |
40, 100 mg SC* |
40mg SC is licensed in patients aged 6-11 weighing less than 40kg, and 100mg SC is licensed in patients aged 6-11 weighing 40kg and over.
*Depending on subject bodyweight
Adverse event profile in paediatric patients aged 6-11 years
Number (%) of Subjects
Mepolizumab |
Mepolizumab |
Overall |
|
---|---|---|---|
Any adverse event |
20 (77) |
6 (60) |
26 (72) |
Related to study treatment |
8 (31) |
3 (30) |
11 (31) |
Leading to withdrawal |
1 (4) |
0 |
1 (3) |
Any serious adverse event |
6 (23) |
1 (10) |
7 (19) |
Related to study treatment |
2 (8) |
0 |
2 (6) |
Fatal serious adverse event |
0 |
0 |
0 |
Any on-treatment** adverse event |
18 (69) |
6 (60) |
24 (67)* |
Any on-treatment** severe adverse event |
5 (19) |
1 (10) |
6 (17) |
**Any AE commencing within 4 weeks of the last dose of Nucala.
*Overall phase 3 AE incidence was 82% for placebo and 79% for mepolizumab 100mg SC
Study 200363 Part B: Adverse events in children aged 6-11 years. 18
Mepo SC |
Mepo SC |
Mepo SC |
Overall |
|
---|---|---|---|---|
Any AE |
15 (94) |
8 (80) |
4 (100) | 27 (90) |
Related to study treatment |
5 (31) |
3 (30) |
1 (25) |
9 (30) |
Leading to withdrawal |
0 |
0 |
0 |
0 |
Any Serious AE |
4 (25) |
2 (20) |
1 (25) |
7 (23) |
Related to study treatment |
0 |
0 |
0 |
0 |
Fatal serious AE |
0 |
0 |
0 |
0 |
Any on-treatment** AE |
15 (94) |
8 (80) |
4 (100) |
27 (90) |
Any on-treatment** severe AE |
4 (25) |
2 (20) |
1 (25) |
7 (23) |
**Any AE commencing within 4 weeks of the last dose of Nucala.
*Subjects enrolled to <40 kg at Visit 9 are summarised in the 40/100 mg SC group if they had weight ≥40 kg at any subsequent visit.
In study 200363, patients under 40kg received a 40mg SC dose, and over 40kg received a 100mg dose. 16
See also:
Quick links:
Exacerbation reduction by baseline eosinophil levels 20
Nucala demonstrates powerful reduction in exacerbations across eosinophil levels. Nucala reduced exacerbations in patients with blood eosinophil levels of ≥150 cells/μL. In a post-hoc analysis there was a trend for a greater reduction in exacerbations with increasing baseline eosinophil levels was observed 20
Reduction in frequency of clinically significant exacerbations vs. placebo by baseline blood eosinophil counts (MENSA Study Population)* 20
Post-hoc analysis of MENSA examining the rate of exacerbations across eosinophils count
*Data from all mepolizumab doses were combined for the analysis (75mg IV, 100mg SC).
Exacerbation reduction by baseline IgE levels 21
Nucala demonstrated powerful reductions in exacerbation across baseline IgE levels demonstrating the efficacy in patients with overlapping severe allergic and severe eosinophilic disease.* 21
Nucala reduced exacerbations by 55% in patients eligible for treatment with omalizumab and by 54% in patients who were ineligible for treatment with omalizumab.** 21
*Data from a post hoc meta-analysis of two Phase III, placebo-controlled, randomised, double-blind, parallel-group, multicentre studies (MENSA and MUSCA).21
**Eligibility defined as having a positive skin test for any of five aeroallergens (house dust mite, dog dander, cat dander, alternaria, and cockroach) and EU/Japan-specific body weight vs. pre-treatment serum IgE combinations.21
Exacerbation reduction switching from omalizumab 22
Nucala provides powerful reduction in exacerbations in uncontrolled patients directly switched from omalizumab. Results show clinically significant reduction in exacerbations with Nucala vs. prior 12 months with omalizumab treatment*. Patients with uncontrolled severe eosinophilic asthma despite omalizumab use were directly switched to Nucala without requirement for a washout period. 22
*Secondary endpoint.
*secondary endpoint; 24-week study.
Improvement in Quality of Life 2
Nucala demonstrated significant improvement in quality of life (SGRQ) vs. placebo seen from week 4 and maintained throughout the study.2
**Primary endpoint; 24-week study.
See also:
Abbreviations:
ACQ, Asthma Control Questionnaire; CI, confidence interval; ED, emergency department; FEV1, forced expiratory volume in 1 second; HRQoL; health related quality of life; ICS, inhaled corticosteroids; IL, interleukin; IV, intravenous; OCS, oral corticosteroids; PD, pharmodynamic; PK, pharmokinetic; SAE, severe adverse events; SoC, standard of care; SQRG, St. George´s Respiratory Questionnaire
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 6
Indication:
Severe Eosinophilic Asthma
NUCALA is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 6 years and older
Dosage:
Adults and Adolescents (12 years and older)
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children aged 6 to 11 years old:
Children weighing ≥ 40 kg
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children weighing < 40 kg
The recommended dose is 40 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks
References:
- GlaxoSmithKline Data on File REF-26441.
- Chupp GL et al. Lancet Respir Med 2017; 5:390-400.
- Bel EH et al. N Engl J Med 2014; 371:1189-1197.
- Khatri S et al. J Allergy Clin Immunol 2019; 143:1742-1751.e7 (including supplementary materials).
- Ortega HG et al. N Engl J Med 2014; 371:1198-2107.
- Local Nucala Prescribing Information based on GDS 12.
- Busse W et al. J Allergy Clin Immunol 2019; 143:190-200.e20.
- Farne HA et al. Cochrane Database Syst Rev 2017; 9:CD010834.
- Lugogo N et al. Clin Ther 2016; 38:2058–2070.
- GINA. Difficult-to-treat & severe asthma in adolescent and adult patients.
- Price D et al. J Asthma Allergy 2016; 9:1-12.
- Garcia G et al. Eur Respir Rev 2013; 22:251-257.
- Wen T, Rothenburg ME. Microbiol Spectr 2016; 4(5): doi:10.1128/microbiolspec.MCHD-0020-2015.
- Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746-760.
- Khatri S et al. J Allergy Clin Immunol 2019; 143:1742-1751.e7.
- GlaxoSmithKline Data on File REF-2175.
- GlaxoSmithKline Data on File REF-2573.
- Steinfeld J, et al. Am J Respir Crit Care Med 2019;199:A7192.
- Ortega H et al. Am J Respir Crit Care Med 2018;197:A1367.
- Ortega HG et al. Lancet Respir Med 2016; 4:549–556.
- Humbert M et al. Resp Med. 2019; 154:69-75.
- Chapman KR, et al. Allergy. 2019. [Epub ahead of print]. doi: 10.1111/all.13850.
Nucala is registered trademark of the GlaxoSmithKline Group of Companies
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 6